Profitelligence Profitelligence · Filing Ledger Open IQV research →

Form 8-K · Current Report · Filed 2025-07-22

IQVIA Reports Strong Second-Quarter 2025 Financial Results

IQVIA Holdings Inc. reported a revenue of $4,017 million for the second quarter of 2025, a 5.3 percent increase from the same period last year. The company reported GAAP Net Income of $266 million and Adjusted EBITDA of $910 million. IQVIA also updated its full-year 2025 guidance, expecting revenue between $16,100 million and $16,300 million, Adjusted EBITDA between $3,750 million and $3,825 million, and Adjusted Diluted Earnings per Share between $11.75 and $12.05.

Filer
Iqvia Holdings Inc. IQV · NYSE
Filed
Accession
0001478242-25-000102
CIK
0001478242
Signal
Low impactHealthcare

Items reported

Item 2.02

Results of Operations and Financial Condition

General Statement
Item 9.01

Financial Statements and Exhibits

Exhibits Furnished

Market reaction

Close before filing

$158.96

Next session

+22.2%

Since filing

+47.8%

Latest close

$235.02

What happened, not what will happen — closing prices around the filing date.

Precedent

Previous filings from IQV reporting the same item, with the next session's move:

Exhibits (1)

About Iqvia Holdings Inc.

Iqvia Holdings Inc. is a leading global provider of advanced analytics, technology solutions, and contract research services. Its primary function is to support the healthcare sector by offering data-driven insights and innovations that underpin strategic decision-making across pharmaceutical, biotechnology, and medical device industries. Iqvia plays a crucial role in facilitating drug development through its comprehensive clinical research capabilities, encompassing everything from clinical trials to regulatory submissions. Additionally, its technology solutions leverage artificial intelligence and machine learning to optimize clinical and commercial operations, contributing to enhanced patient outcomes and streamlined healthcare delivery. Iqvia's integrated services impact sectors such as drug safety, patient engagement, and real-world evidence, making it an indispensable partner for healthcare companies seeking to navigate complex markets and regulatory environments. Globally recognized for its vast data repository and cutting-edge analytical platforms, Iqvia serves as a pivotal player in the transformation of the healthcare landscape, empowering organizations to accelerate innovation and improve patient care.

Exchange NYSE Industry Diagnostics & Research Company website ↗

Never miss another IQV filing

Profitelligence watches EDGAR around the clock and alerts you within seconds.

Set up free alerts